<DOC>
	<DOC>NCT00994123</DOC>
	<brief_summary>A Phase 1-2 study of MM-121 in combination with standard therapy for non-small cell lung cancer (NSCLC).</brief_summary>
	<brief_title>A Study of MM-121 Combination Therapy in Patients With Advanced Non-Small Cell Lung Cancer</brief_title>
	<detailed_description>Phase 1: Patients with Non-Small Cell Lung Cancer (NSCLC) may be enrolled to evaluate the safety, tolerability and recommended Phase 2 dose of MM-121 in combination with standard therapy. Phase 2: Patients with Non-Small Cell Lung Cancer (NSCLC) may be enrolled to estimate the progression-free survival of the MM-121 + standard therapy.</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>Patients with locally advanced or metastatic nonsmall cell lung cancer. Patients must be &gt;/= 18 years of age. Patients must have adequate Performance Status (PS) as measured by ECOG and adequate end organ function. Patients with a recent history (within 5 years) of another malignancy. Patients who are pregnant or nursing. Patients with clinically significant heart failure. Patients with clinically significant eye or gastrointestinal abnormalities.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Non-Small Cell Lung Cancer</keyword>
	<keyword>NSCLC</keyword>
	<keyword>Advanced Non-Small Cell Lung Cancer</keyword>
	<keyword>Metastatic Non-Small Cell Lung Cancer</keyword>
	<keyword>Lung Cancer</keyword>
	<keyword>Erlotinib</keyword>
	<keyword>Tarceva</keyword>
	<keyword>MM-121</keyword>
	<keyword>ErbB3</keyword>
	<keyword>Her3</keyword>
	<keyword>Epidermal Growth Factor Receptor</keyword>
	<keyword>anti-ErbB3 human monoclonal antibody</keyword>
	<keyword>ErbB3 antagonist</keyword>
</DOC>